Key Highlights
- H1 2026 results (6 August 2026) showed revenue of roughly $1.23bn and organic growth of 5.0% excluding the InnovaMatrix skin-substitute line.
- The interim dividend was lifted about 15% and the board launched a $200m share buyback to be completed by the end of 2026.
- InnovaMatrix revenue collapsed to about $2.5m from roughly $39m a year earlier after a Medicare pricing change of more than 85% gutted the product's economics, triggering a $69m non-cash impairment.
- Full-year organic growth guidance was narrowed to 5.5%-6.5% (excluding InnovaMatrix), with management guiding to 6-8% organic growth in H2, led by a return to double-digit growth in Infusion Care.
- Adjusted operating margin was 21.2%, roughly flat on a reported basis but up around 50 basis points at constant currency, with the gap reflecting unfavourable currency translation.
- Infusion Care led divisional growth at 7.4% to about $246m; Continence Care grew 5.9%, Ostomy Care 4.3%, and Advanced Wound Care 3.4%.
A Case for Momentum Reasserting Itself
ConvaTec Group used its interim results on 6 August 2026 to make a simple case to investors: the first half was solid, and the second is meant to be better. The FTSE 100 medical products group reported half-year revenue of roughly $1.23bn and organic growth of 5.0% once its troubled InnovaMatrix skin-substitute line is stripped out, while guiding that organic growth should accelerate to 6-8% in the second half.
Management paired that outlook with a clear signal on capital returns. The interim dividend was lifted about 15% and the board launched a $200m share buyback to be completed by the end of 2026. For a company whose recent narrative has been dominated by a single collapsing product line, the message was one of underlying momentum reasserting itself as the year progresses.
A Chronic-Care Specialist Across Four Divisions
ConvaTec is a London-listed medical technology group focused on chronic-care categories where products are used repeatedly over long periods. Its business spans four divisions: Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care, the last of which supplies insulin-pump infusion sets and related consumables and accounts for close to a fifth of group revenue. The company generates the bulk of its sales from consumable, recurring products rather than one-off capital equipment, which lends the revenue base a degree of resilience. Jonny Mason serves as chief executive and Fiona Ryder as chief financial officer, a new leadership team following the death of former chief executive Karim Bitar in 2025.
The Half-Year Numbers and Divisional Detail
Reported revenue rose 4.4% to about $1,232m, with organic growth of 5.0% excluding InnovaMatrix. Adjusted operating profit came in near $262m, up around 3.9%, and adjusted diluted earnings per share reached 8.5 cents, roughly 6% higher year on year. Alongside the numbers, the group narrowed its full-year organic growth guidance to 5.5-6.5% (excluding InnovaMatrix) from a previous 5-7% range, and reaffirmed a full-year adjusted operating margin target of at least 23%.
Divisionally, Advanced Wound Care grew 3.4% to about $354m, Ostomy Care rose 4.3% to roughly $353m, Continence Care advanced 5.9% to around $277m and Infusion Care led the field with 7.4% growth to some $246m. The adjusted operating margin was 21.2%, ten basis points lower than a year earlier on a reported basis but up around 50 basis points at constant currency, the gap reflecting an unfavourable foreign-exchange translation effect. The interim dividend was set at 2.166 cents, a 15% increase.
The InnovaMatrix Shock
The most visible risk crystallised in the first half. InnovaMatrix revenue collapsed to about $2.5m, down from roughly $39m a year earlier, after a Medicare pricing change of more than 85% gutted the product's economics. The group took a $69m non-cash impairment charge and now expects the line to contribute only $5-10m for the full year, a headwind of around 2.5 percentage points to group revenue growth. The episode is a reminder of how exposed medical suppliers can be to reimbursement decisions — a regulatory or pricing move by a major payer such as US Medicare can reshape the economics of a product line almost overnight.
The Case for Second-Half Acceleration
Set against the first half of 2025, the results show a business growing more slowly but holding its margin. A year ago the group delivered organic growth of about 6.8% and an adjusted operating margin of 21.3%. The deceleration in headline organic growth is largely explained by tougher comparatives and phasing rather than a structural loss of momentum, which is why the second-half guidance matters so much. Management pointed to new product launches, improving commercial execution, seasonal weighting towards the second half and productivity savings as the levers expected to drive both the H2 revenue acceleration and a step-up in margin towards roughly 25% in the second half.
Outlook
The first-half numbers describe a company growing steadily, protecting its margin against currency headwinds and returning more cash to shareholders, but one whose growth rate has cooled from a year ago and whose credibility now rests heavily on a second-half acceleration it has yet to deliver. The interim result is best characterised as reassuring rather than spectacular: the reported figures were historical and solid, the buyback and dividend are concrete, but the more exciting part of the story — 6-8% growth and a sharply higher second-half margin — remains management guidance.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...